Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tion of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assump
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... NEW YORK , March 5, 2015  DuPont ... J.P. Morgan Aviation, Transportation and Industrials Conference held today ... Vice President Matthew L. Trerotola discussed strategy, ... Advanced Materials segments for DuPont.  Strengthening and growing the ... of the three areas of strategic priority for DuPont. ...
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the ... President of Managed Care. In this role, Damm will ... the nation’s leading specialty pharmacies. , Damm, who is ... specialty pharmacy and biotech experience to his new position ... Pharmaceuticals, and Pfizer. Prior to working in Healthcare Damm ...
(Date:3/5/2015)... and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) has announced ... New Therapy Ventures Pave the Way for Success" ... companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) ... positive return and hence increased the interest of biotech ... indication where the high treatment cost justifies the need. ...
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... , 3.75% Convertible Senior Notes due May 1, 2015 (May ... principal amount or approximately $5.72 per share, effective March 3, 2015. ... adjusted in connection with the regular quarterly dividend of $0.15 ... own shares of PDL on March 5, 2015, the record date. ...
Breaking Biology Technology:DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... Bard, James Burke,s Connections, Jacob Bronowski,s Ascent of Man, as well as ... , ... New York, NY (PRWEB) January 15, 2009 -- Stream the ... hundreds of other award winning programs now available at ambrosedigital.com ., ...
... of Americans Want President-Elect Obama to Deliver on Campaign ... - WASHINGTON, Jan. 14 The Coalition for the ... paper, Catalyst For Cures: Embryonic Stem Cell Research ... nation,s leading scientists on the promises and challenges of ...
... Helps Hospitals and Health Systems Reduce the Likelihood ... Recovery Audit ContractorPHOENIX, Jan. 14 Arizona-based Cain ... the launch of its new Government Audit ... as a pre-review process to assist hospitals and ...
Cached Biology Technology:New Video Streaming Site Created by Ambrose Video Publishing 2New Video Streaming Site Created by Ambrose Video Publishing 3Coalition for the Advancement of Medical Research Releases New White Paper, 'Catalyst for Cures: Embryonic Stem Cell Research' 2Coalition for the Advancement of Medical Research Releases New White Paper, 'Catalyst for Cures: Embryonic Stem Cell Research' 3Cain and Associates Launches Government Audit Protection (GAP) Service 2Cain and Associates Launches Government Audit Protection (GAP) Service 3
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), ... general the State of Washington,s Department ... new enrollment and central issuance system for driver,s licenses and ... The project planning and development will start in January 2015, ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... of applications to develop utility-scale solar power installations in ... little is known to judge their likely effects on ... 2011 issue of BioScience . Although solar power ... information suggests a worrisome range of possible impacts. These ...
... paleoclimate history by NASA,s Goddard Institute for Space Studies ... climate changes this century, including multiple meters of sea ... By looking at how the Earth,s climate responded to ... question raised by ongoing human-caused climate change: "What is ...
... a fraction of truck-borne freight onto trains would have an ... researchers at the University of WisconsinMadison. Much of that ... a graduate student in UWMadison,s Nelson Institute for Environmental Studies. ... miles on a gallon of diesel fuel. Trains can move ...
Cached Biology News:Solar power development in US Southwest could threaten wildlife 2Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4For Midwesterners, more boxcars mean cleaner air 2
...
...
... Comments: Ab-1 stains tumor cells of embryonal carcinoma ... of germ cell tumors like seminoma. Glandular epithelium ... positive. Luminal and endocrine cells of stomach and ... are also positive. Epitope: Carbohydrate portion ...
TP-1 (NDOG1)...
Biology Products: